SECTION EDITOR: EDWARD W. COWEN, MD, MHSc; ASSISTANT SECTION EDITORS: MURAD ALAM, MD; RUTH ANN VLEUGELS, MD
Angiosarcoma (AS) of the scalp is a rare and aggressive neoplasm with one of the worst prognoses among malignant skin tumors. The overall 5-year survival rate is less than 30%.1 Specific treatment guidelines are absent, and treatment options include surgical excision, radiation therapy, chemotherapy (CT), and biological therapy such as recombinant interleukin 2 (rIL-2). Surgical excision with negative margins combined with CT is the most successful strategy for improving the prospect for survival.2,3
Ono S, Tanioka M, Fujisawa A, Tanizaki H, Miyachi Y, Matsumura Y. Angiosarcoma of the Scalp Successfully Treated With a Single Therapy of Sorafenib. Arch Dermatol. 2012;148(6):683–685. doi:10.1001/archdermatol.2011.2819
Coronavirus Resource Center
Customize your JAMA Network experience by selecting one or more topics from the list below.